Summit Therapeutics (SMMT) Receivables - Net (2017 - 2022)
Summit Therapeutics' (SMMT) quarterly Receivables - Net came in at $349000.0 in Q4 2022, down 76.16% YoY from $1.5 million in Q4 2021, and up 149.29% on a QoQ basis from $140000.0 in Q3 2022.
Summit Therapeutics (SMMT) Receivables - Net (2017 - 2022) Analysis & Trends
Summit Therapeutics (SMMT) has 6 years of Receivables - Net data on file, last reported at $349000.0 in Q4 2022.
- Quarterly Receivables - Net fell 76.16% year-over-year to $349000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $349000.0 (down 76.16% YoY) and the FY2022 annual result came in at $349000.0, down 76.16% from the prior year.
- Receivables - Net grew to $349000.0 in Q4 2022, from $140000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $17.3 million in Q1 2019 to a low of $140000.0 in Q3 2022.
- A 5-year average of $5.7 million and a median of $1.9 million in 2021 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2018 — Receivables - Net soared 1072.16% — and 2020, when it plunged 96.83%.
- Tracing SMMT's Receivables - Net over 5 years: stood at $14.9 million in 2018, then sank by 30.16% to $10.4 million in 2019, then tumbled by 96.83% to $331000.0 in 2020, then surged by 342.3% to $1.5 million in 2021, then plunged by 76.16% to $349000.0 in 2022.
- The last three Receivables - Net figures came in at $349000.0 (Q4 2022), $140000.0 (Q3 2022), and $238000.0 (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 349,000.00 |
| Dec 31, 2022 | 349,000.00 |
| Sep 30, 2022 | 140,000.00 |
| Sep 30, 2022 | 140,000.00 |
| Jun 30, 2022 | 238,000.00 |
| Jun 30, 2022 | 238,000.00 |
| Mar 31, 2022 | 870,000.00 |
| Mar 31, 2022 | 870,000.00 |
| Dec 31, 2021 | 1.46 Mn |
| Dec 31, 2021 | 1.46 Mn |
| Sep 30, 2021 | 2.30 Mn |
| Sep 30, 2021 | 2.30 Mn |
| Jun 30, 2021 | 1.05 Mn |
| Jun 30, 2021 | 1.05 Mn |
| Mar 31, 2021 | 447,000.00 |
| Mar 31, 2021 | 447,000.00 |
| Dec 31, 2020 | 331,000.00 |
| Dec 31, 2020 | 331,000.00 |
| Sep 30, 2020 | 4.08 Mn |
| Sep 30, 2020 | 4.08 Mn |